Step2c trial for new, drug-susceptible lung TB
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and agree to HIV testing before starting study procedures.
- You are age 18 to 65 and weigh 40 to 90 kg (no shoes, light clothing).
- Your TB test results show TB in the lungs that is susceptible to rifampin (RIF) and isoniazid (INH), confirmed by rapid tests like GeneXpert or HAIN.
- Your chest X-ray (done within 2 weeks) and sputum (phlegm) results support that you have active, drug-susceptible lung TB.
- You can follow food rules during the study and are able to use effective contraception during the study and for a set time after the last dose (or you are not able to get pregnant/be a parent).
- You do not have key health exclusions (for example: significant liver/kidney problems, certain heart rhythm issues, pregnancy/breastfeeding, or HIV with very low CD4).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.